Killexams.com ST0-116 Dumps and existent Questions
100% existent Questions - Exam Pass Guarantee with elevated Marks - Just Memorize the Answers
ST0-116 exam Dumps Source : Symantec Data Loss Prevention 11(R) Technical Assessment
Test Code : ST0-116
Test cognomen : Symantec Data Loss Prevention 11(R) Technical Assessment
Vendor cognomen : Symantec
: 176 existent Questions
can i learn dumps Q & A of ST0-116 examination?
nicely, I did it and that i cant trust it. I could in no way gain passed the ST0-116 with out your assist. My score changed intoso elevated i used to exist amazed at my overall performance. Its just because of you. thanks very an Awful lot!!!
those ST0-116 dumps works in the actual check.
a few rightly men cant carry an alteration to the worlds way however they are able to best let you know whether you gain got been the only guy who knew a way to try this and that i exigency to exist regarded in this world and beget my own heed and i gain been so lame my entire way but I know now that I wanted to bag a skip in my ST0-116 and this could beget me illustrious perhaps and yes i am brief of glory however passing my A+ exams with killexams.com became my morning and night glory.
Passing ST0-116 exam became my first savor but much enjoy!
I subscribed on killexams.com with the aid of the suggession of my buddy, as a way to bag some greater useful resourcefor my ST0-116 checks. As quickly as I logged on to this killexams.com I felt relaxed and relieved on account that I knew this could encourage me bag thru my ST0-116 test and that it did.
can i learn existent acquire a perceive at questions Q & A present day ST0-116 examination?
To become a ST0-116 Certified, I was in thrust to pass the ST0-116 exam. I tried and failed final 2 attempts. Accidently, I got the killexams.com material through my cousin. I was very impressed with the material. I secured 89%. I am so satisfied that I scored above the margin heed without difficulty. The material is nicely formatted as well as enriched with necessary concepts. I reckon it is the much selection for the exam.
Questions had been exactly identical as I got!
It is a captains job to steer the ship just enjoy it is a pilots job to steer the plane. This killexams.com can exist called my captain or my pilot because it steered me in to the birthright direction before my ST0-116 test and it was their directions and guidance that got me to result the birthright path that eventually lead me to success. I was very successful in my ST0-116 test and it was a jiffy of glory for which I will forever remain obliged to this online study center.
Extract concurrent plenary ST0-116 path contents in layout.
When I had taken the conclusion for going to the exam then I got a sterling back for my preparation from the killexams.com which gave me the realness and reliable rehearse ST0-116 prep classes for the same. Here, I also got the break to bag myself checked before fervor confident of performing well in the way of the preparing for ST0-116 and that was a nice thing which made me consummate ready for the exam which I scored well. Thanks to such things from the killexams.
you recognize the fine and fastest manner to pass ST0-116 examination? I got it.
I although that if I may additionally want to pellucid their ST0-116 check and confident this is as soon as I got here to recognise with my antique top class buddy that killexams.com is the one that would exist the boon for me because it were given me my intelligence finally again which I had misplaced for some time and that i want that this may in no manner bag over for me getting my ST0-116 check cleared in the end.
Surprised to observe ST0-116 dumps!
killexams.com gave me an excellent preparation tool. I used it for my ST0-116 exam and got a maximum score. I treasure the way killexams.com does their exam preparation. Basically, this is a dump, so you bag questions that are used on the existent ST0-116 exams. But the exam simulator and the rehearse exam format encourage you memorize it plenary very well, so you End up learning things, and will exist able to draw upon this information in the future. Very sterling quality, and the exam simulator is very light and user friendly. I didnt gain across any issues, so this is excellent value for money.
it's far genuinely first rate savor to gain ST0-116 state-statemodern dumps.
To bag success in ST0-116 exam. human beings accept as accurate with that a scholar exigency to possess sharp brain. although it is undoubted but it isnt absolutely actual in view that along with the scholar, the instruct or the trainer ought to also exist rightly certified and educated. I savor blessed that i used to exist familiar with this killexams.com in which I met such brilliant educators who taught me how to pellucid my ST0-116 test and were given me through them with a breeze. I thank them with the bottom of my coronary heart.
Get the ones ST0-116 actual exam questions and answers! execute now not bag ripplatestf
I might acquire a privilege to mention Many Many way to plenary team individuals of killexams.com for presenting the sort of tremendous platform made to exist had to us. With the encourage of the web questions and caselets, i gain efficaciously cleared my ST0-116 certification with 81% marks. It become truly advantageous to apprehend the sort and patterns of questions and reasons provided for solutions made my principles crystal smooth. Thank you for plenary the manual and maintain doing it. plenary of the character killexams.
Symantec Symantec Data Loss Prevention
Symantec (Nasdaq: SYMC), the realm's main cyber security company, today announced it has acquired an "In technique” designation from the Federal chance and Authorization administration application (FedRAMP) for its Cloud entry security broking service (CASB) and data Loss Prevention (DLP) solutions below sponsorship of the department of autochthonous land safety (DHS).
Named a pacesetter via trade analysts, Symantec’s CASB solution allows for agencies to confidently leverage cloud applications and services in a secure, comfy and compliant method. It offers visibility into shadow IT, enforces governance over statistics in cloud applications and gives insurance map in opposition t threats focused on cloud bills and functions. Symantec’s DLP solution offers a separate console and unified policy management for every channel – cloud, endpoints, storage, e mail and net – to assist give protection to sensitive facts anywhere it is used throughout these channels.
"Symantec continues to exist dedicated to assisting executive agencies give protection to their most constructive asset – their facts,” stated Chris Townsend, vp of federal at Symantec. "We acquire into account the exciting challenges their federal shoppers kisser and are making strategic investments to back them securely and confidently migrate to the cloud. Getting their items FedRAMP approved indicates their commitment to the executive and positions us a depended on companion and consultant.”
An "In system” designation indicates that a Cloud provider provider (CSP) is actively working on the documentation and controls required to obtain a FedRAMP authorization, and that an company is reviewing that documentation with the intent to deliver an Authority to operate that meets the FedRAMP requirements. CSPs deemed as "In system” are positioned on the FedRAMP market, which highlights cloud provider choices with FedRAMP designations.
CASB and DLP are the latest Symantec choices to lag in the course of the FedRAMP authorization procedure. In February, Symantec’s e mail safety provider – govt bought FedRAMP authorization, and Symantec has a roadmap centered for its different cloud security tools and items to recede in the course of the FedRAMP certification system.
Symantec’s strategy is to assist clients meet the challenges of the cloud generation via its built-in Cyber defense Platform, unifying coverage for both cloud-based mostly purposes and on-premises tools and technologies. This enables a cohesive fashion to possibility management, presenting obligatory visibility, context and manage to achieve a far better protection baseline for the executive. Symantec plans to bring this means on AWS GovCloud at the tolerable baseline.
Symantec organisation (NASDAQ: SYMC), the area's main cyber protection business, helps companies, governments and individuals comfy their most censorious records at any set it lives. agencies the world over perceive to Symantec for strategic, built-in solutions to preserve in opposition t sophisticated attacks across endpoints, cloud and infrastructure. Likewise, a world community of greater than 50 million americans and households signify on Symantec's Norton and LifeLock product suites to present protection to their digital lives at home and across their devices. Symantec operates one of the world's biggest civilian cyber intelligence networks, enabling it to perceive and give protection to towards the most superior threats. For more information, gratify visit www.symantec.com or combine with us on facebook, Twitter, and LinkedIn.
View source edition on businesswire.com: https://www.businesswire.com/news/home/20181203005890/en/
Symantec presents a complete strategy to information loss prevention that covers both on-premises and cloud environments, in addition to cell devices.
The antivirus supplier's fashion to statistics loss prevention (DLP) has advanced rather just a miniature over the final decade. Symantec bought DLP maker Vontu in 2007, and they integrated the enterprise's know-how into the Symantec protection suite. Symantec's DLP providing later expanded to covered numerous components, together with Symantec DLP for Cloud Storage, Symantec DLP Cloud prevent for Microsoft workplace 365, Symantec information Loss Prevention for Endpoint, Symantec records Loss Prevention for cellular, Symantec records Loss Prevention network and Symantec facts Loss Prevention for Storage.
these days, the product is integrated with the cloud access security broker capabilities of the Symantec CloudSOC. The current version of Symantec data Loss Prevention, 14.6, includes integration with products from Blue Coat techniques, which Symantec obtained in 2016.
Symantec statistics Loss Prevention's structure incorporates content-mindful detection servers and endpoint brokers, plus a unified administration platform. The suite is scalable to lots of of thousands of users and gadgets. it may possibly even exist deployed on premises, in hybrid cloud environments and as a managed provider through a Symantec managed safety service issuer associate.
Amazon internet capabilities (AWS) steer allows for DLP content material detection servers to exist deployed on AWS infrastructure. This enables agencies to monitor and protect exquisite facts establish in AWS-hosted circumstances of Microsoft trade and SharePoint.
On the different conclusion of the spectrum, the DLP administration server, content material detection servers and Oracle database can also exist deployed on a separate actual server for little businesses or far off workplaces, thereby decreasing hardware and maintenance charges.
cellular insurance policy
The Symantec facts Loss Prevention suite also includes monitoring for cellular contraptions and mobile email via Symantec DLP for mobile with cell e-mail monitor and cellular evade. cell email pomp screen helps Android and iOS contraptions and may notice when employees download exquisite corporate records to their mobiles devices the usage of the Microsoft alternate ActiveSync protocol.
commercial enterprise and endpoint insurance plan
normal commercial enterprise architectures are supported with a yoke of tools and accessories within the Symantec facts Loss Prevention suite.
For the Symantec facts Loss Prevention for Endpoint product, the Symantec DLP Endpoint find and Symantec Endpoint avoid modules control statistics in use. These modules fulfill autochthonous scanning, detection and monitoring for macOS, windows 7, windows 8 and windows 10 machines.
On the endpoints, these modules also computer screen and manage cloud storage sync folders, Outlook and Lotus Notes electronic mail purchasers, HTTP/HTTPS and FTP protocol site visitors, removable storage media -- akin to USB, media transfer protocol, CompactFlash and SD playing cards -- plus eSATA and FireWire for moveable drives. The modules also video pomp and manage digital desktops, reminiscent of Citrix, Microsoft Hyper-V and VMware.
statistics in motion is addressed with the aid of Symantec DLP network pomp screen, community remain away from for e-mail and network evade for net. information at relaxation is monitored using Symantec DLP network discover, community protect, statistics perception and the statistics perception Self-provider Portal.
The suite helps cloud deployments with Symantec DLP for Cloud Storage and Cloud remain away from for Microsoft workplace 365.
Symantec DLP for Cloud Storage is an information-at-leisure device that scans realm company and commercial enterprise bills. it might probably aid investigate the set sensitive suggestions is being saved, the way it's used and who is receiving it. It will also exist configured to assist clients amend policy violations by way of inserting visible tags on realm files so clients can remediate policy violations the usage of the Symantec DLP Self-provider Portal.
The Cloud File Sync and share feature maintains users from syncing sensitive statistics data from their computer to cloud file sharing sites corresponding to field, Dropbox, Google power, Hightail, iCloud and Microsoft OneDrive.
Symantec DLP Cloud avoid for Microsoft office 365, meanwhile, monitors and controls emails sent from Microsoft office 365 cases of Microsoft alternate on-line. it works with current Symantec DLP guidelines for change, enabling a company to migrate its change servers to the cloud.
The Symantec facts Loss Prevention suite is designed to meets the wants of tremendous companies, in addition to little and medium-sized companies. The product covers quite a lot of areas, including endpoint statistics in use, network information in transit, and files and databases at rest. Symantec statistics Loss Prevention addresses on-premises, cell and cloud records and can exist deployed on both physical servers -- home windows Server, red Hat trade Linux and others -- and cloud infrastructures, corresponding to AWS. Symantec is at present readying edition 15 of the product, even though a free up date has now not been made public yet.
businesses interested in Symantec facts Loss Prevention may noiseless contact the dealer or an authorized reseller partner for pricing and other suggestions.
BARCELONA, SPAIN--(Marketwire -10/04/11)- Symantec imaginative and prescient 2011 -- Symantec Corp. (NASDAQ: SYMC - news) nowadays announced it is planning to present Symantec statistics Loss Prevention for pill, the first complete records loss prevention (DLP) solution for the monitoring and insurance policy of exquisite tips on tablet computer systems. attainable first for the Apple iPad, Symantec information Loss Prevention for tablet will back remedy one of the vital pressing problems facing safety groups today by offering content-aware protection for this remarkably accepted modern corporate endpoint. The solution is designed to preserve user productiveness and give protection to a firm's private records on the very time.
examine extra unavoidable blog submit:
in line with Symantec's fresh situation of security Survey, businesses are grappling with modern security challenges stemming from the proliferation of pills in the business. Of those surveyed, 47 percent pointed out mobile computing changed into making it more difficult to provide on-line safety, and 45 percent said the "consumerization of IT" changed into a priority. The latter class contains modern technologies that cross over from purchaser to enterprise markets, with pills changing laptops because the excellent subject. As users carry pills into the enterprise and entry the company community, it is faced with the challenge of retaining exquisite company records on those endpoints.
click to Tweet: Symantec launches DLP for pill: http://bit.ly/nRY66h
Symantec facts Loss Prevention for pill will permit clients to beget the most of the drugs they are disturbing while monitoring and controlling the transmission of personal facts from these instruments with content material focus. The product is designed to allow organizations to steer toil and personal expend at the very time as across company and personal e mail, internet communications, and customary functions attainable for the iPad. The insurance policy will extend to the gear and counsel on it regardless of whether the consumer is related by the expend of 3G or Wi-Fi. encourage for the Android pill working gadget is additionally scheduled to exist purchasable next 12 months.
Symantec records Loss Prevention for pill could exist the newest addition to Symantec DLP and cellular administration options. The product is designed to let current Symantec DLP consumers leverage their current investment via employing the very guidelines and administration infrastructure. The company additionally offers a complete set of encryption solutions ranging from plenary disk encryption and detachable storage to email and server solutions. These consist of the currently introduced Symantec PGP Viewer for iOS. The viewer makes it practicable for employees of organizations with Symantec PGP commonplace Server in vicinity to read encrypted messages on their favored Apple iOS instruments including the iPad and iPhone as an example, govt group contributors can acquire and reckon about encrypted copies of a sales file with assurance that both its privacy and security are intact.
prices"With the great boom in tablet adoptions, purchasers gain struggled the way to lengthen assistance protection to this modern consumer instrument because it makes its way onto the trade networks," referred to artwork Gilliland, senior vice chairman, assistance protection neighborhood, Symantec. "Symantec statistics Loss Prevention for pill will allow IT to superior encourage their companies in adopting this modern know-how, whereas also holding mighty protections for their exquisite tips."
"while CISOs and security companies exigency to exist seen as enterprise enablers who embody the newest productivity equipment, first they should exist capable of exist unavoidable the private information on these gadgets may exist blanketed," mentioned Jon Oltsik, foremost analyst, trade approach group. "The extension of DLP merits to the most recent corporate endpoint, the iPad, will encourage them to satisfy both sides of the equation."
Availability and Pricing Symantec facts Loss Prevention for tablet is expected to exist obtainable for the iPad in early 2012. The product might exist priced per tablet. encourage for the Android tablet working system is scheduled to comply with. Symantec PGP Viewer for iOS is an Apple iOS software at the jiffy attainable for down load from the Apple App keep.
connect with Symantec
About Symantec Symantec is a world chief in presenting security, storage and methods management options to assist patrons and companies at ease and manipulate their suggestions-driven world. Their software and functions present protection to in opposition t greater dangers at greater facets, more absolutely and effectively, enabling self-possession anyplace information is used or stored. more counsel is available at www.symantec.com.
ahead searching Statements: Any forward-searching indication of plans for items is preparatory and plenary future unencumber dates are tentative and are theme to trade. Any future liberate of the product or planned changes to product capability, performance, or feature are realm to ongoing contrast via Symantec, and may or may additionally no longer exist applied and will no longer exist regarded enterprise commitments by way of Symantec and should no longer exist relied upon in making deciding to buy selections.
word TO EDITORS: if you would enjoy additional information on Symantec organisation and its items, gratify talk over with the Symantec information play at http://www.symantec.com/news. plenary expenditures celebrated are in U.S. greenbacks and are legitimate only within the u.s..
Symantec and the Symantec emblem are logos or registered emblems of Symantec organisation or its associates within the U.S. and other nations. different names may exist trademarks of their respective house owners.
Technorati TagsSymantec, drugs, records loss prevention, iPad facts protection, information breach, information coverage
While it is very arduous job to elect reliable certification questions / answers resources with respect to review, reputation and validity because people bag ripoff due to choosing wrong service. Killexams.com beget it confident to serve its clients best to its resources with respect to exam dumps update and validity. Most of other's ripoff report complaint clients gain to us for the brain dumps and pass their exams happily and easily. They never compromise on their review, reputation and character because killexams review, killexams reputation and killexams client self-possession is principal to us. Specially they acquire care of killexams.com review, killexams.com reputation, killexams.com ripoff report complaint, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. If you observe any erroneous report posted by their competitors with the cognomen killexams ripoff report complaint internet, killexams.com ripoff report, killexams.com scam, killexams.com complaint or something enjoy this, just hold in intellect that there are always detestable people damaging reputation of sterling services due to their benefits. There are thousands of satisfied customers that pass their exams using killexams.com brain dumps, killexams PDF questions, killexams rehearse questions, killexams exam simulator. Visit Killexams.com, their sample questions and sample brain dumps, their exam simulator and you will definitely know that killexams.com is the best brain dumps site.
Back to Braindumps Menu
050-728 questions and answers | 642-584 bootcamp | 70-332 existent questions | 050-ENVCSE01 pdf download | 70-767 rehearse questions | HH0-130 sample test | M2010-727 rehearse test | 1Z0-516 exam questions | 922-093 study guide | E22-214 braindumps | C2010-657 test prep | HP2-K26 rehearse Test | 000-M235 existent questions | C9560-654 questions and answers | 920-328 dump | LOT-805 brain dumps | 000-562 braindumps | 000-M248 study guide | FN0-202 braindumps | M2040-669 VCE |
Take a gander at these ST0-116 existent question and answers
We are doing battle to giving you actual Symantec Data Loss Prevention 11(R) Technical Assessment exam questions and answers, alongside explanations. Each on killexams.com has been confirmed by Symantec certified specialists. They are exceptionally qualified and confirmed people, who gain numerous times of expert savor identified with the Symantec exams.
We gain their specialists operating ceaselessly for the gathering of existent test questions of ST0-116. plenary the pass4sure Questions and Answers of ST0-116 collected by their team are verified and updated by their Symantec certified team. they gain an approach to remain connected to the candidates appeared within the ST0-116 exam to induce their reviews regarding the ST0-116 exam, they gain an approach to collect ST0-116 exam tips and tricks, their expertise regarding the techniques utilized in the principal ST0-116 exam, the mistakes they wiped out the principal exam then improve their braindumps consequently.
Once you stand their pass4sure Questions and Answers, you will feel assured regarding plenary the topics of exam and feel that your information has been greatly improved. These killexams.com Questions and Answers are not simply rehearse questions, these are existent test Questions and Answers that are enough to pass the ST0-116 exam first attempt.
killexams.com Discount Coupons and Promo Codes are as under;
WC2017 : 60% Discount Coupon for plenary exams on website
PROF17 : 10% Discount Coupon for Orders larger than $69
DEAL17 : 15% Discount Coupon for Orders larger than $99
SEPSPECIAL : 10% Special Discount Coupon for plenary Orders
If you are inquisitive about success passing the Symantec ST0-116 exam to start earning? killexams.com has forefront developed Symantec Data Loss Prevention 11(R) Technical Assessment test questions that will beget confident you pass this ST0-116 exam! killexams.com delivers you the foremost correct, current and latest updated ST0-116 exam questions and out there with a 100 percent refund guarantee. There are several firms that present ST0-116 brain dumps however those are not amend and latest ones. Preparation with killexams.com ST0-116 modern questions will exist a best thing to pass this certification test in straightforward means.
killexams.com gain their experts Team to guarantee their Symantec ST0-116 exam questions are dependably the most current. They are at the total extraordinarily familiar with the exams and testing consciousness.
How killexams.com maintain Symantec ST0-116 exams updated?: they gain their uncommon procedures to realize the maximum recent exams statistics on Symantec ST0-116. Now after which they palpate their accomplices who're especially at ease with the exam simulator recognition or once in a while their customers will email us the latest enter, or they were given the most current update from their dumps carriers. When they learn the Symantec ST0-116 exams changed then they updates them ASAP.
On the off prep that you honestly gain up quick this ST0-116 Symantec Data Loss Prevention 11(R) Technical Assessment and might elect no longer to sit tight for the updates then they will give you plenary refund. however, you should forward your score respond to us with the goal that they will gain a exam. They will give you plenary refund quick amid their working time when they bag the Symantec ST0-116 score document from you.
Symantec ST0-116 Symantec Data Loss Prevention 11(R) Technical Assessment Product Demo?: they gain both PDF model and Testing Software. You can exam their product web page to perceive what it would look that like.
At the point when will I bag my ST0-116 cloth once I pay?: Generally, After successful payment, your username/password are sent at your e mail cope with within 5 min. It may also acquire miniature longer in case your answers postpone in pervade authorization.
killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for plenary tests on website
PROF17 : 10% Discount Coupon for Orders extra than $69
DEAL17 : 15% Discount Coupon for Orders extra than $ninety nine
DECSPECIAL : 10% Special Discount Coupon for plenary Orders
ST0-116 Practice Test | ST0-116 examcollection | ST0-116 VCE | ST0-116 study guide | ST0-116 practice exam | ST0-116 cram
Killexams EE0-021 existent questions | Killexams 351-050 VCE | Killexams HP0-J14 study guide | Killexams 117-302 free pdf | Killexams HPE6-A43 free pdf | Killexams HP2-B85 bootcamp | Killexams 000-646 pdf download | Killexams P5050-031 rehearse Test | Killexams HP3-C35 cheat sheets | Killexams ST0-303 existent questions | Killexams 000-M01 questions answers | Killexams HP2-E27 rehearse test | Killexams MB3-208 rehearse test | Killexams 00M-662 study guide | Killexams TB0-110 dumps | Killexams M8060-655 exam prep | Killexams TMPTE dump | Killexams 00M-604 test questions | Killexams HP0-621 braindumps | Killexams 000-314 exam prep |
killexams.com huge List of Exam Study Guides
Killexams 70-343 dumps questions | Killexams 1Z0-430 existent questions | Killexams 000-997 exam prep | Killexams M2020-745 rehearse Test | Killexams HP0-815 existent questions | Killexams ICDL-EXCEL braindumps | Killexams 9A0-384 brain dumps | Killexams 3M0-212 rehearse test | Killexams 000-886 rehearse questions | Killexams 9L0-504 rehearse questions | Killexams JN0-411 questions answers | Killexams HP5-H01D rehearse exam | Killexams 000-851 braindumps | Killexams HP2-E47 free pdf download | Killexams 00M-235 test questions | Killexams 1Z1-514 free pdf | Killexams 9A0-318 mock exam | Killexams AVA questions and answers | Killexams 000-M75 brain dumps | Killexams HP0-D14 study guide |
Symantec Data Loss Prevention 11(R) Technical Assessment
Pass 4 confident ST0-116 dumps | Killexams.com ST0-116 existent questions | https://www.textbookw.com/
No result found, try modern keyword!Add to this their first acquisition in years of 3VR [Technical rigor ... more RFID transponders, more loss prevention platforms. But longer term when you reckon about it, the existent problem in securit...
Updated: May 25, 2018:
JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.
Please note that if you subscribe to one of their Services, you can beget choices about how they collect, expend and share your information through their Privacy hub under the "My Account" dashboard (available if you are logged into your JD Supra account).
Collection of Information
Registration Information. When you register with JD Supra for their Website and Services, either as an author or as a subscriber, you will exist asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:
Other Information: They also collect other information you may voluntarily provide. This may comprehend content you provide for publication. They may also receive your communications with others through their Website and Services (such as contacting an author through their Website) or communications directly with us (such as through email, feedback or other forms or gregarious media). If you are a subscribed user, they will also collect your user preferences, such as the types of articles you would enjoy to read.
Information from third parties (such as, from your employer or LinkedIn): They may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you elect to expend LinkedIn to subscribe to their Website and Services, they also collect information related to your LinkedIn account and profile.
Your interactions with their Website and Services: As is accurate of most websites, they gather unavoidable information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. They expend this information to analyze trends, to administer the Website and their Services, to improve the content and performance of their Website and Services, and to track users' movements around the site. They may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. They also expend cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may expend on their Website and Services gratify observe their "Cookies Guide" page.
How execute they expend this information?
We expend the information and data they collect principally in order to provide their Website and Services. More specifically, they may expend your personal information to:
Operate their Website and Services and publish content;
Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about their policies and terms);
Measure readership and usage of the Website and Services;
Communicate with you regarding your questions and requests;
Authenticate users and to provide for the safety and security of their Website and Services;
Conduct research and similar activities to improve their Website and Services; and
Comply with their legal and regulatory responsibilities and to enforce their rights.
How is your information shared?
Content and other public information (such as an author profile) is shared on their Website and Services, including via email digests and gregarious media feeds, and is accessible to the general public.
If you elect to expend their Website and Services to communicate directly with a company or individual, such communication may exist shared accordingly.
Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to encourage them to improve their content.
Your information may also exist shared to parties who back their business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
Any court, governmental authority, law enforcement agency or other third party where they believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect their rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
To their affiliated entities and in connection with the sale, assignment or other transfer of their company or their business.
How They Protect Your Information
JD Supra takes reasonable and arrogate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. They restrict access to user information to those individuals who reasonably exigency access to fulfill their job functions, such as their third party email service, customer service personnel and technical staff. You should hold in intellect that no Internet transmission is ever 100% secure or error-free. Where you expend log-in credentials (usernames, passwords) on their Website, gratify remember that it is your responsibility to safeguard them. If you believe that your log-in credentials gain been compromised, gratify contact us at email@example.com.
Our Website and Services are not directed at children under the age of 16 and they execute not knowingly collect personal information from children under the age of 16 through their Website and/or Services. If you gain intuition to believe that a child under the age of 16 has provided personal information to us, gratify contact us, and they will endeavor to delete that information from their databases.
Links to Other Websites
Our Website and Services may hold links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using their Website or Services and click a link to another site, you will leave their Website and this Policy will not apply to your expend of and activity on those other sites. They encourage you to read the legal notices posted on those sites, including their privacy policies. They are not responsible for the data collection and expend practices of such other sites. This Policy applies solely to the information collected in connection with your expend of their Website and Services and does not apply to any practices conducted offline or in connection with any other websites.
Information for EU and Swiss Residents
JD Supra's principal set of trade is in the United States. By subscribing to their website, you expressly consent to your information being processed in the United States.
Right of Access/Portability: You can anticipate to review details about the information they hold about you and how that information has been used and disclosed. Note that they may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
Right to amend Information: You may anticipate that they beget corrections to any information they hold, if you believe such correction to exist necessary.
Right to Restrict Their Processing or Erasure of Information: You also gain the birthright in unavoidable circumstances to anticipate us to restrict processing of your personal information or to delete your personal information. Where you gain consented to their expend of your personal information, you can withdraw your consent at any time.
You can beget a request to exercise any of these rights by emailing us at firstname.lastname@example.org or by writing to us at:
Privacy OfficerJD Supra, LLC10 Liberty Ship Way, Suite 300Sausalito, California 94965
You can also manage your profile and subscriptions through their Privacy hub under the "My Account" dashboard.
We will beget plenary practical efforts to respect your wishes. There may exist times, however, where they are not able to fulfill your request, for example, if applicable law prohibits their compliance. gratify note that JD Supra does not expend "automatic conclusion making" or "profiling" as those terms are defined in the GDPR.
Onward Transfer to Third Parties: As celebrated in the "How They share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, they gain ensured that such third parties gain either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process plenary personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they gain been subjected to strict contractual provisions in their condense with us to guarantee an adequate flat of data protection for your data.
California Privacy Rights
Pursuant to Section 1798.83 of the California Civil Code, their customers who are California residents gain the birthright to request unavoidable information regarding their disclosure of personal information to third parties for their direct marketing purposes.
You can beget a request for this information by emailing us at email@example.com or by writing to us at:
Privacy OfficerJD Supra, LLC10 Liberty Ship Way, Suite 300Sausalito, California 94965
Some browsers gain incorporated a execute Not Track (DNT) feature. These features, when turned on, forward a signal that you prefer that the website you are visiting not collect and expend data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, they currently execute not respond to DNT signals on their site.
Access/Correct/Update/Delete Personal Information
For non-EU/Swiss residents, if you would enjoy to know what personal information they gain about you, you can forward an e-mail to firstname.lastname@example.org. They will exist in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. They will respond within 30 days to your request for access to your personal information. In some cases, they may not exist able to remove your personal information, in which case they will let you know if they are unable to execute so and why. If you would enjoy to amend or update your personal information, you can manage your profile and subscriptions through their Privacy hub under the "My Account" dashboard. If you would enjoy to delete your account or remove your information from their Website and Services, forward an e-mail to email@example.com.
Contacting JD Supra
As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and their services (such as their email article digests)(our "Services") expend a touchstone technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are little data files that are transferred to your computer when you expend their Website and Services. These technologies automatically identify your browser whenever you interact with their Website and Services.
How They expend Cookies and Other Tracking Technologies
We expend cookies and other tracking technologies to:
Improve the user savor on their Website and Services;
Store the authorization token that users receive when they login to the private areas of their Website. This token is specific to a user's login session and requires a convincing username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
Track anonymous site usage; and
Permit connectivity with gregarious media networks to permit content sharing.
There are different types of cookies and other technologies used their Website, notably:
"Session cookies" - These cookies only final as long as your online session, and evaporate from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
"Persistent cookies" - These cookies remain on your computer or device after your browser has been closed and final for a time specified in the cookie. They expend persistent cookies when they exigency to know who you are for more than one browsing session. For example, they expend them to remember your preferences for the next time you visit.
"Web Beacons/Pixels" - Some of their web pages and emails may also hold little electronic images known as web beacons, pellucid GIFs or single-pixel GIFs. These images are placed on a web page or email and typically toil in conjunction with cookies to collect data. They expend these images to identify their users and user behavior, such as counting the number of users who gain visited a web page or acted upon one of their email digests.
JD Supra Cookies. They set their own cookies on your computer to track unavoidable information about you while you are using their Website and Services. For example, they set a session cookie on your computer each time you visit their Website. They expend these cookies to allow you to log-in to your subscriber account. In addition, through these cookies they are able to collect information about how you expend the Website, including what browser you may exist using, your IP address, and the URL address you came from upon visiting their Website and the URL you next visit (even if those URLs are not on their Website). They also utilize email web beacons to monitor whether their emails are being delivered and read. They also expend these tools to encourage deliver reader analytics to their authors to give them insight into their readership and encourage them to improve their content, so that it is most useful for their users.
Analytics/Performance Cookies. JD Supra also uses the following analytic tools to encourage us analyze the performance of their Website and Services as well as how visitors expend their Website and Services:
HubSpot - For more information about HubSpot cookies, gratify visit legal.hubspot.com/privacy-policy.
New Relic - For more information on modern Relic cookies, gratify visit www.newrelic.com/privacy.
Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across plenary websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.
Facebook, Twitter and other gregarious Network Cookies. Their content pages allow you to share content appearing on their Website and Services to your gregarious media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, they embed code that such third party gregarious networks provide and that they execute not control. These buttons know that you are logged in to your gregarious network account and therefore such gregarious networks could also know that you are viewing the JD Supra Website.
Controlling and Deleting Cookies
The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to execute so with a particular browser, you can expend your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.
Updates to This Policy
Contacting JD Supra
If you gain any questions about how they expend cookies and other tracking technologies, gratify contact us at: firstname.lastname@example.org.
Preconception testing of motivated populations for recessive disease mutations, together with education and genetic counseling of carriers, can markedly reduce disease incidence within a generation. Tay-Sachs disease [TSD; Online Mendelian Inheritance in Man (OMIM) accession number 272800], for example, is an autosomal recessive neurodegenerative disorder with onset of symptoms in infancy and death by 2 to 5 years of age. Formerly, the incidence of TSD was 1 per 3600 Ashkenazi births in North America (1, 2). After 40 years of preconception screening in this population, however, the incidence of TSD has been reduced by more than 90% (2–5). Although TSD remains incurable, therapies are available for many stern recessive diseases of childhood. Thus, in addition to disease prevention, preconception testing could enable perinatal diagnosis and treatment, which can profoundly diminish disease severity.
Although individual Mendelian diseases are uncommon in general populations, collectively, they account for ~20% of infant mortality and ~10% of pediatric hospitalizations (6, 7). Over the past 25 years, 1139 genes that intuition Mendelian recessive diseases gain been identified (8). To date, however, preconception carrier testing has been recommended in the United States only for five of these: brittle X syndrome (OMIM #300624) in selected individuals; cystic fibrosis (OMIM #219700) in Caucasians; and TSD, Canavan disease (OMIM #271900), and familial dysautonomia (OMIM #223900) in individuals of Ashkenazi descent (9–13). A framework for the progress of criteria for comprehensive preconception screening can exist inferred from an American College of Medical Genetics (ACMG) report on expansion of newborn screening for inherited diseases (14). Criteria included test accuracy and cost, disease severity, highly penetrant recessive inheritance, and whether an intervention was available for those identified. These criteria are also material for expansion of preconception carrier screening. Hitherto, principal criteria precluding extension of preconception screening to most stern recessive mutations or the general population gain been cost [defined in that report as an overall analytical cost requirement of <$1 per test per condition (14)] and the absence of accurate, sensitive, scalable technologies.
Target capture and next-generation sequencing (NGS) gain shown efficacy and, recently, scalability for resequencing human genomes and exomes, providing an alternative potential paradigm for comprehensive carrier testing (15–22). In genome research, an tolerable depth of sequence coverage of 30-fold has been accepted as sufficient for single-nucleotide polymorphism (SNP) and nucleotide insertion or deletion (indel) detection (15–22). However, acceptable false-positive and false-negative rates for routine expend in clinical rehearse are more stringent and are driven by the intended purpose for which the data are to exist used. Data demonstrating the sensitivity and specificity of genotyping of disease mutations, particularly polynucleotide indels, vulgar insertions and deletions, copy number variations (CNVs), and complex rearrangements, are very limited (20–22). In particular, the accuracy of disease mutation genotypes derived from NGS of enriched targets has been uncertain.
A recent workshop provided recommendations for qualification of modern methodologies for broader population-based carrier screening (23). These were elevated analytical validity, concordance in many settings, elevated throughput, and cost-effectiveness (including sample acquisition and preparation). Here, they report the progress of a preconception carrier screen for 448 stern recessive childhood disease genes, based on target enrichment and NGS that meets most of these criteria, and expend of the screen to assess carrier affliction for stern recessive diseases of childhood.
The carrier test reported herein was based on several hypotheses. First, cost-effectiveness was assumed to exist censorious for test adoption. The incremental cost associated with increasing the degree of multiplexing was assumed to diminish toward an asymptote. Thus, very broad coverage of diseases was assumed to present optimal cost-benefit. Second, comprehensive mutation sets, allele frequencies in populations, and individual mutation genotype-phenotype relationships gain been defined in very few recessive diseases. In addition, some studies of cystic fibrosis carrier screening for a few common alleles gain shown decreased prevalence of tested alleles with time, rather than reduced disease incidence (24, 25). These two lines of evidence suggested that very broad coverage of mutations offered the greatest likelihood of substantial reductions in disease incidence with time. Third, physician, patient, and societal adoption of screening was assumed to exist optimal for the most stern and highly penetrant childhood diseases, before conception and where the anticipated clinical validity and clinical utility of testing was pellucid (26). Therefore, diseases were chosen that would almost certainly change family planning by prospective parents or palpate antenatal, perinatal, or neonatal care. Milder recessive disorders, such as deafness, and adult-onset diseases, such as inherited cancer syndromes, were omitted, as were conditions lacking tough evidence for causal mutations (26).
Database and literature searches and expert reviews were performed on 1123 diseases with recessive inheritance of known molecular basis (8, 27, 28). In general, diseases were selected to meet ACMG guidelines for genetic testing for rare, highly penetrant disorders (26). Assessment of the clinical validity and utility of testing was primarily based on literature review and was challenging for some disorders because of the paucity of data. Several subordinate requirements were gathered: In view of pleiotropy and variable severity, disease genes were included if mutations caused stern illness in a symmetry of affected children. plenary but six diseases that featured genocopies (including variable inheritance and mitochondrial mutations) were included. Diseases were not excluded on the basis of low incidence. Diseases for which great population carrier screens exist were included, such as TSD, hemoglobinopathies, and cystic fibrosis. Mental retardation genes were not included in this iteration. Four hundred and forty-eight X-linked recessive and autosomal recessive diseases, encompassing 437 genes, met these criteria (table S1). The disease ilk was cardiac for 8, cutaneous for 45, developmental for 46, endocrine for 15, gastroenterological for 3, hematological for 15, hepatic for 3, immunological for 29, metabolic for 142, neurological for 122, ocular for 12, renal for 25, respiratory for 8, and skeletal for 28. Note that these genes, although a sterling representative set, require further assessment of clinical readiness before translation into clinical testing.
Array hybridization with allele-specific primer extension was initially favored for expanded carrier detection because of test simplicity, cost, scalability, and accuracy, as has recently been described (29). To exist well suited for array-based screening, however, most carriers must exist accounted for by a few mutations, and most disease mutations must exist nucleotide substitutions (8, 27, 28). Of 215 autosomal recessive disorders examined, only 87 were assessed to meet these criteria. Most recessive disorders for which a great symmetry of affliction was attributable to a few disease mutations were limited to specific ethnic groups. Indeed, 286 stern childhood autosomal recessive diseases encompassed 19,640 known disease mutations (8, 27, 28). Given that the Human Gene Mutation Database (HGMD) lists 102,433 disease mutations (27), a number that is steadily increasing, a fixed-content fashion appeared impractical. Other concerns with array-based screening for recessive disorders were ilk 1 errors in the absence of confirmatory testing and ilk 2 errors for disease mutations other than substitutions (complex rearrangements, indels, or vulgar deletions with uncertain boundaries). A serendipitous discovery (discussed below) that supported this conclusion was an unexpectedly elevated number of characterized mutations that are misannotated.
The effectiveness and remarkable decline in cost of exome capture and NGS for variant detection in genomes and exomes suggested an alternative potential paradigm for comprehensive carrier testing. Four target enrichment and three NGS methods were preliminarily evaluated for multiplexed carrier testing. preparatory experiments suggested that existing protocols for Agilent SureSelect hybrid capture (15) and RainDance microdroplet polymerase chain reaction (PCR) (16) but not Febit HybSelect microarray-based biochip capture (30) or Olink padlock probe ligation and PCR (31) yielded consistent target enrichment. Therefore, workflows and software pipelines were developed for comprehensive carrier testing by hybrid capture or microdroplet PCR, followed by NGS (Fig. 1). Baits or primers were designed to capture or amplify 1,978,041 nucleotides (nt), corresponding to 7717 segments of 437 recessive disease genes by hybrid capture and microdroplet PCR, respectively. Targeted were plenary coding exons and splice site junctions, and intronic, regulatory, and untranslated regions known to hold disease mutations (table S2). In general, baits for hybrid capture or PCR primers were designed to encompass or flank disease mutations, respectively. Primers were also designed to avoid known polymorphisms and to minimize nontarget nucleotides. To capture or amplify both the orthodox and the disease mutation alleles, they also designed custom baits or primers for 11 vulgar deletion disease mutations for which boundaries had been defined (table S3). A total of 29,891 120-mer RNA baits were designed to capture 98.7% of targets. Fifty-five percent of 101 exons that failed bait design contained iterate sequences (table S4). Primer pairs (10,280) were designed to amplify 99% of targets (table S5). Twenty exons failed primer design by falling outside the amplicon size ambit of 200 to 600 nt.
Workflow of the comprehensive carrier screening test. Workflow shows receiving samples and DNA extraction, target enrichment from DNA samples, multiplexed sequencing library preparation, NGS, and bioinformatic analysis. (The bioinformatic conclusion tree is shown in fig. S4.)
An model target enrichment protocol would inexpensively result in at least 30% of nucleotides being on target, which corresponded to ~500-fold enrichment with ~2-million-nucleotide target size. This was achieved with hybrid capture after one round of bait redesign for underrepresented exons and decreased bait representation in overrepresented exons (Table 1). An model target enrichment protocol would also give a narrow distribution of target coverage and without tails or skewness (indicative of minimal enrichment-associated bias). After hybrid capture, the sequencing library size distribution was narrow (Fig. 2A). The aligned sequence coverage distribution was unimodal but flat (platykurtic) and right-skewed (Fig. 2B). This implied that hybrid capture would require oversequencing of most targets to recruit a minority of poorly selected targets to adequate coverage. As expected, median coverage increased linearly with sequence depth. The symmetry of bases with greater than zero and >20× coverage increased toward asymptotes at ~99 and ~96%, respectively (Table 1 and Fig. 2C). Targets with low (<3×) coverage were highly reproducible and had elevated GC content (table S6). This suggested that targets failing hybrid capture could exist predicted and, perhaps, rescued by individual PCRs.
Sequencing, alignment, and coverage statistics for target enrichment and sequencing platforms.
Analytic metrics of multiplexed carrier testing by NGS. (A) Chromatograms of size distributions of sequencing libraries after target enrichment. Top: Target enrichment by hybrid capture. Bottom: Target enrichment by microdroplet PCR. Size markers are shown at 40 and 8000 nt. FU, fluorescence units. (B) Frequency distribution of target coverage after hybrid selection and 1.75 Gb of singleton 50-mer Illumina GAIIx SBS of sample NA13675. Aligned sequences had a character score of >25. (C) Target coverage as a function of depth of sequencing across 104 samples and six experiments. (D) Frequency distribution of target coverage after microdroplet PCR and 1.49 Gb of singleton 50-mer SBS of sample NA20379. Aligned sequences had a character score of >25.
Given the exigency for highly accurate carrier detection, they required >10 uniquely aligned reads of character score >20 and >14% of reads to summon a variant (20, 21). The requirement for >10 reads was highly efficacious for nucleotides with moderate coverage. For heterozygote detection, for example, this was equivalent to ~20× coverage, which was achieved in ~96% of exons with ~2.6 gigabases (Gb) of sequence (Fig. 2C). The symmetry of targets with at least 20× coverage appeared to exist useful for character assessment. The requirement for ≥14% of reads to summon a variant was highly efficacious for nucleotides with very elevated coverage and was derived from the genotype data discussed below. A character score requirement was principal when NGS started, but is now largely redundant.
In theory, microdroplet PCR should result in plenary cognate amplicons being on target and should induce minimal bias. In practice, the coverage distribution was narrower than hybrid capture but with similar birthright skewing (Fig. 2D). However, these results were complicated by ~11% recurrent primer synthesis failures. This resulted in linear amplification of a subset of targets, ~5% of target nucleotides with zero coverage and a similar symmetry of nucleotides on target to that obtained in the best hybrid capture experiments (~30%; Table 1). Hybrid capture was used for subsequent studies for reasons of cost.
Multiplexing of samples during hybrid selection and NGS had not previously been reported. Six- and 12-fold multiplexing was achieved by adding molecular bar codes to adaptor sequences. Interference of bar code nucleotides with hybrid selection did not occur appreciably: The stoichiometry of multiplexed pools was essentially unchanged before and after hybrid selection. Multiplexed hybrid selection was establish to exist ~10% less efficacious than singleton selection, as assessed by median fold enrichment. Less than 1% of sequences were discarded at alignment because of bar code sequence ambiguity. Therefore, up to 12-fold multiplexing at hybrid selection and per sequencing lane (equivalent to 96-plex per sequencing current cell) was used in subsequent studies to achieve the targeted cost of <$1 per test per sample.
Several NGS technologies are currently available. Of these, the Illumina sequencing-by-synthesis (SBS) and SOLiD sequencing-by-ligation (SBL) platforms are widely disseminated and gain throughput of at least 50 Gb per flee and read lengths of at least 50 nt. Therefore, the character and quantity of sequences from multiplexed, target-enriched libraries were compared with SBS (GAIIx singleton 50-mer) and SBL (SOLiD3 singleton 50-mer; Table 1). SBS- and SBL-derived 50-mer sequences (and alignment algorithms) gave similar alignment metrics (Table 1). When compared with Infinium array results, specificity of SNP genotypes by SBS and SBL was very similar (SBS, 99.69%; SBL, 99.66%), reflecting both target enrichment and multiplexed sequencing (Fig. 3).
Venn diagrams of specificity of on-target SNP calls and genotypes in six samples. Target nucleotides were enriched by hybrid selection and sequenced by Illumina GAIIx SBS and SOLiD3 SBL at sixfold multiplexing. The samples were also genotyped with Infinium Omni1-Quad SNP arrays. (A) Comparison of SNP calls and genotypes obtained by SBS, SBL, and arrays at nucleotides surveyed by plenary three methods. SNPs were called if present in >10 uniquely aligning SBS reads, >14% of reads, and with tolerable character score of >20. Heterozygotes were identified if present in 14 to 86% of reads. Numbers refer to SNP calls. Numbers in brackets refer to SNP genotypes. (B) Comparison of SNP calls and genotypes obtained by SBS, SBL, and arrays. SNPs were called if present in more than four uniquely aligning SBS reads, >14% of reads, and with tolerable character score of >20. Heterozygotes were identified if present in 14 to 86% of reads.
Given approximate parity of throughput and accuracy, consideration was given to optimal read length. Unambiguous alignment of short-read sequences is typically confounded by repetitive sequences, but was not material for carrier testing, because targets overwhelmingly contained unique sequences. The number of mismatches tolerated for unique alignment of short-read sequences is highly constrained but increases with read length. The vast majority of disease mutations are single-nucleotide substitutions or little indels. However, comprehensive carrier testing also requires detection of polynucleotide indels, vulgar insertions, vulgar deletions, and complex rearrangements. A combination of bioinformatic approaches was used to overcome short-read alignment shortcomings (Fig. 4). First, with the Illumina HiSeq SBS platform, they used the novel approach of read pair assembly before alignment (99% efficiency) to generate longer reads with high-quality scores (148.6 ± 3.8 nt combined read length and increase in nucleotides with character score >30 from 75 to 83%). This was combined with generation of 150-nt sequencing libraries without gel purification by optimization of DNA shearing procedures and expend of silica membrane columns. Omission of gel purification was censorious for scalability of library generation. Second, they reduced the penalty on polynucleotide variants, rewarding identities (+1) and penalizing mismatches (−1) and indels [−1−log(indel − length)]. Third, vulgar deletions were detected both by consummate alignment to mutant junction reference sequences and by local decreases in normalized coverage (normalized to total sequence generated; C. H. Hu, personal communication). Previous studies gain identified CNVs on the basis of changes in regional coverage along a chromosome in an individual sample (20, 21). However, concomitant analysis of normalized coverage in batches of samples appears to circumvent the exigency for adjustment for GC content (32), allowing more accurate detection of segmental losses. This was illustrated by identification of eight known vulgar deletion disease mutations (Fig. 5). Furthermore, seeking consummate alignment to mutant junction reference sequences obviates low alignment scores when short reads containing polynucleotide variants are mapped to a orthodox reference. This was illustrated by identification of 11 vulgar deletion mutations for which boundaries had been defined (table S3). It is anticipated that these approaches could exist extended to vulgar insertions and complex rearrangements but will require additional analytical validation.
Decision tree to classify sequence variation and evaluate carrier status. After reads were aligned to references, substitution, insertion, and deletion events and their associated character metrics were recorded. Variants were classified as heterozygous or homozygous and annotated by comparison with mutation databases. Variants not in the mutation databases were evaluated for putative functional consequence and were retained as disease mutations if predicted to result in protein truncation. Variants with a frequency of <5% among plenary samples and that were known to intuition a disease phenotype or loss of protein function and that were only establish as homozygous in affected individuals were retained and reported.
Detection of vulgar deletion mutations by local reduction in normalized aligned reads. (A) Deletion of CLN3 introns 6 to 8, 966bpdel, exons7-8del and fs, chr16:28405752_28404787del in four known compound heterozygotes (NA20381, NA20382, NA20383, and NA20384; red diamonds) and one undescribed carrier (NA00006; green diamond) among 72 samples sequenced. (B) Heterozygous deletion in HBA1 (chr16:141620_172294del, 30,676-bp deletion from 5′ of ζ2 to 3′ of θ1 in ALU regions) in one known (NA10798; red diamond; normalized coverage, 26; weigh in normalized coverage, 61.9 ± 15.2) and two undescribed carriers [NA19193 (normalized coverage, 28) and NA01982 (normalized coverage, 31); green diamonds] among 72 samples. Heterozygous deletion in NA10798 was confirmed by array hybridization. (C) Known homozygous deletion of exons 7 and 8 of SMN1 in one of eight samples (NA03813; red diamond). (D) Detection of a vulgar deletion that is a intuition of Duchenne muscular dystrophy (OMIM #310200, DMD exons 51 to 55 del, chrX:31702000_31555711del) by reduction in normalized aligned reads at chrX:31586112. Among 72 samples, one (NA04364; red diamond) was from an affected male, and another (NA18540, a female JPT/HAN HapMap sample) was determined to carry a deletion that extends to at least chrX:31860199 [see (E)]. (E) An undescribed heterozygous deletion of DMD 3′ exon 44–3′ exon 50 (chrX:32144956-31702228del) in NA18540 (green diamond), a JPT/HAN HapMap sample. This deletion extends from at least chrX:31586112 to chrX:31860199 [see (D)]. Sample NA05022 (red diamond) is the uncharacterized mother of an affected son with 3′ exon 44–3′ exon 50 del, chrX:32144956-31702228del. Given the absence of the mutation in the mother, it likely occurred de novo in the son, as observed in one-third of DMD patients (62). (F) Hemizygous deletion in PLP1 exons3_4, c.del349_495del, chrX:102928207_102929424del in one (NA13434; red diamond) of eight samples. (G) Absence of vulgar deletion CG984340 (ERCC6 exon 9, c.1993_2169del, 665_723del, exon 9 del, chr10:50360915_50360739del) in 72 DNA samples. The sample in red (NA01712) was incorrectly annotated to exist a compound heterozygote with CG984340 on the basis of cDNA sequencing.
On the basis of these strategies and their previous savor of genotyping variants identified in next-generation genome and chromosome sequences (20, 21, 33, 34), a bioinformatic conclusion tree for genotyping disease mutations was developed (Fig. 4). Clinical utility of target enrichment, SBS sequencing, and this conclusion tree for genotyping disease mutations was assessed. SNPs in 26 samples were genotyped by both high-density arrays and sequencing. The distribution of read count–based allele frequencies of 92,106 SNP calls was trimodal, with peaks corresponding to homozygous reference alleles, heterozygotes, and homozygous variant alleles, as ascertained by array hybridization (Fig. 6B). Optimal genotyping cutoffs were 14 and 86% (Fig. 6B). With these cutoffs and a requirement for 20× coverage and 10 reads of character ≥20 to summon a variant, the accuracy of sequence-based SNP genotyping was 98.8%, sensitivity was 94.9%, and specificity was 99.99%. The positive predictive value (PPV) of sequence-based SNP genotypes was 99.96% and negative predictive value (NPV) was 98.5%, as ascertained by array hybridization. As sequence depth increased from 0.7 to 2.7 Gb, sensitivity increased from 93.9 to 95.6%, whereas PPV remained ~100% (Fig. 6A). Areas under the curve (AUCs) of the receiver operating characteristic (ROC) for SNP calls by hybrid capture and SBS were calculated. When genotypes in 26 samples were compared with genome-wide SNP array hybridization, the AUC was 0.97 when either the number or the percent reads calling a SNP were varied (Fig. 6, C and D). When the parameters were combined, the AUC was 0.99. For known substitution, indel, splicing, vulgar deletion, and regulatory alleles in 76 samples, sensitivity was 100% (113 of 113 known alleles; table S7). The higher sensitivity for detection of known mutations reflected manual curation. The 20 known indels were confirmed by PCR and Sanger sequencing. Notably, substitutions, indels, splicing mutations, and vulgar deletions account for the vast majority (96%) of annotated mutations (27).
Clinical metrics of multiplexed carrier testing by NGS. (A) Comparison of 92,128 SNP genotypes by array hybridization with those obtained by target enrichment, SBS, and a bioinformatic conclusion tree in 26 samples. SNPs were called if present in >10 uniquely aligning reads, >14% of reads, and tolerable character score of >20. Heterozygotes were identified if present in 14 to 86% of reads. TP = SNP called and genotyped correctly. TN = reference genotype called correctly. FN = SNP genotype undercall. FP = SNP genotype overcall. Accuracy = (TP + TN)/(TP + FN + TN + FP). Sensitivity = TP/(TP + FN). Specificity = TN/(TN + FP). Positive predictive value (PPV) = TP/(TP + FP). Negative predictive value (NPV) = TN/(TN + FN). (B) Distribution of allele frequencies of SNP calls by hybrid capture and SBS in 26 samples. Light blue, heterozygotes by array hybridization. (C) Receiver operating characteristic (ROC) curve of sensitivity and specificity of SNP genotypes by hybrid capture and SBS in 26 samples (when compared with array-based genotypes). Genomic regions with less than 20× coverage were excluded. Upon varying the number of reads calling the SNP, the district under the curve (AUC) was 0.97. (D) ROC curve of SNP genotypes by hybrid capture and SBS in 26 samples. Genomic regions with less than 20× coverage were excluded. Upon varying the percent reads calling the SNP, AUC was 0.97.
Unexpectedly, 14 of 113 literature-annotated disease mutations were either incorrect or incomplete (table S7) (35–,39). PCR and Sanger sequencing confirmed that the 14 variants and genotypes called by NGS were correct. For example, sample NA07092, from a male with X-linked recessive Lesch-Nyhan syndrome (OMIM #300322), was characterized as a deletion of HPRT1 exon 8 by complementary DNA (cDNA) sequencing (40), but had an explanatory splicing mutation (intron 8, IVS8+1_4delGTAA, chrX:133460381_133460384delGTAA; Fig. 7A). NA09545, from a male with XLR Pelizaeus-Merzbacher disease (PMD; OMIM #312080), characterized as a substitution disease mutation [PLP1 exon 5, c.767C>T, P215S (41)], was establish to also feature PLP1 gene duplication [which is reported in 62% of sporadic PMD (42); Fig. 7B]. NA02057, from a female with aspartylglucosaminuria (OMIM #208400), characterized as a compound heterozygote, was homozygous for two adjacent substitutions (AGA exon 4, c.482G>A, R161Q, chr4:178596918G>A and exon 4, c.488G>C, C163S, chr4:178596912G>C in 38 of 39 reads; Fig. 8), of which C163S had been shown to exist the disease mutation (43). Although one allele of NA01712, a CHT with Cockayne syndrome ilk B (OMIM #133540), had been characterized by cDNA analysis as a deletion of ERCC6 exon 9 [c.1993_2169del, p.665_723del, exon 9 del, chr10:50360915_50360739del (44)], no diminish in normalized exon 9 read number was observed despite more than 300× coverage (Fig. 5G). Instead, however, 64 of 138 NA01712 reads contained a nucleotide substitution that created a premature stop codon (Q664X, chr10:50360741C>T). Both ERCC4 mutations described in CHT NA03542 were absent in at least 130 aligning reads (44). However, the current study used DNA from Epstein-Barr virus (EBV)–transformed cell lines in which somatic hypermutation has been celebrated (45). In particular, ERCC4, a DNA repair gene, is a likely candidate for somatic mutation. Including these results, the specificity of sequence-based genotyping of substitution, indel, vulgar deletion, and splicing disease mutations was 100% (97 of 97).
Disease mutations and estimated carrier affliction in 104 DNA samples. (A) Sample NA07092, from an affected male with X-linked recessive Lesch-Nyhan syndrome (OMIM #300322), had been characterized as a deletion of HPRT1 exon 8 by cDNA sequencing (19), but has an explanatory splicing mutation (intron 8, IVS8+1_4delGTAA, chrX:133460381_133460384delGTAA). (B) Sample NA09545, from an affected male with X-linked recessive Pelizaeus-Merzbacher disease (PMD; OMIM #312080), characterized as a substitution disease mutation [PLP1 exon 5, c.767C>T, P215S (20)], also featured PLP1 gene duplication [which is reported in 62% of sporadic PMD (21)]. (C) Distribution of carrier affliction of stern pediatric diseases among 104 DNA samples. (D) Ward hierarchical clustering of 227 stern pediatric disease mutations in 104 DNA samples.
Five reads from NA202057 showing AGA exon 4, c.488G>C, C163S, chr4:178596912G>C and exon 4, c.482G>A, R161Q, chr4:178596918G>A (black arrows). One hundred and ninety-three of 400 reads contained these substitution disease mutations (CM910010 and CM910011). The top lines of doublets are Illumina GAIIx 50-nt reads. The bottom lines are NCBI reference genome, build 36.3. Colors picture character (Q) scores of each nucleotide: red, >30; orange, 20 to 29; green, 10 to 19. Reads aligned uniquely to these coordinates.
The tolerable carrier affliction of stern recessive disease mutations for stern childhood recessive diseases was assessed in 104 DNA samples. plenary variants meeting the filtering criteria described above and flagged as disease mutations in HGMD were enumerated. Seventy-four percent of these, however, were accounted for by 47 substitutions each with an incidence of ≥5%, of which 20 were homozygous in samples unaffected by the corresponding disease (table S8). These were omitted. Literature back for pathogenicity was evaluated for the remaining variants flagged as disease mutations in HGMD. Variants were retained as disease mutations if they had been shown to result in loss of activity in a functional assay, were the only variants detected in affected individuals and absent in controls, and/or were predicted to result in a premature stop codon or loss of a substantial portion of the protein (Fig. 4). In total, 27% (122 of 460) of literature-cited disease mutations were omitted, because they were adjudged to exist common polymorphisms or sequencing errors or because of a exigency of evidence of pathogenicity. New, putatively deleterious variants (variants in stern pediatric disease genes that create premature stop codons or coding domain frameshifts) were quantified: 26 heterozygous or hemizygous modern nonsense variants were identified in 104 samples (table S9). Including the latter, 336 variants were retained as likely disease mutations.
The tolerable carrier affliction of stern recessive substitutions, indels, and vulgar deletion disease mutations, after exclusion of one allele in compound heterozygotes, was 2.8 per genome (291 in 104 samples). The carrier affliction frequency distribution was unimodal with slight birthright skewing (Fig. 7C). The ambit in carrier affliction was surprisingly narrow (zero to seven per genome, with a mode of two; Fig. 7C).
As exemplified by cystic fibrosis, the carrier incidence and mutation spectrum of individual recessive disorders vary widely among populations (46). However, whereas group sizes were small, no significant differences in total carrier affliction were establish between Caucasians and other ethnicities, between males and females, nor between affected and unaffected individuals (after correction for compound heterozygosity in those affected). Hierarchical clustering of samples and disease mutations revealed an apparently random topology, suggesting that targeted population testing is likely to exist ineffective (Fig. 7D). Adequacy of hierarchical clustering was attested to by samples from identical twins being nearest neighbors, as were two disease mutations in linkage disequilibrium.
We gain described a screening test for carriers of 448 stern childhood recessive illnesses consisting of target enrichment, NGS, and bioinformatic analyses, which worked well in a research setting. Specificity was 99.96%, and a sensitivity of ~95% was attained with hybrid capture at a sequence depth of 2.5 Gb per sample. Because enrichment failures with hybrid capture were reproducible, they may exist amenable to rescue by individual PCR or probe redesign. Alternatively, microdroplet PCR should theoretically achieve a sensitivity of ~99%, albeit at higher cost (16, 47). The test was scalable, modular, and amenable to automation, with batches of 192 samples and a turnaround of 2 weeks. The time to first result could exist reduced substantially with microdroplet PCR and third-generation sequencing. At elevated volume, the overall analytical cost of the hybrid enrichment-based test was $378, achieving the requirement of $1 per test per condition and approximating that expended on treatment of stern recessive childhood disorders per U.S. live birth (14, 29). Although the analytical cost will diminish as the throughput of NGS improves, test interpretation, reporting, genetic counseling, and stewardship of mutation databases will confer considerable additional costs.
Having established technical feasibility in a research setting, the next phases of carrier test progress will exist refinement of the list of diseases, automation, software implementation, report development, and, most important, validation in a realistic testing situation featuring investigator blinding and less manual review. For example, genes associated with stern cognitive developmental disorders may merit inclusion. Although technical standards and guidelines gain been established for laboratory-developed genetic testing for rare disorders in accredited laboratories (26), there are several challenges in their adoption for NGS and bioinformatic-based testing of ~500 conditions. For example, specific national standards for character assurance, character control, test accessioning and reporting, and proficiency evaluation execute not currently exist. Addressing crucial issues such as specificity and erroneous positives is complex when hundreds of genes are being sequenced simultaneously. For unavoidable diseases, such as cystic fibrosis, reference sample panels and metrics gain been established. For diseases without such materials, it is prudent to test as many samples containing known mutations as possible. In setting up and validating the screen, it would also exist necessary to test examples of plenary classes of mutations and situations that are anticipated to exist potentially problematic, such as mutations within elevated GC content regions, simple sequence repeats, and repetitive elements.
The ethical, legal, and gregarious implications of comprehensive carrier testing warrant much discussion. These issues, in turn, are influenced by the scope and setting in which testing is proposed. The model age for recessive disease screening is in early adulthood and before pregnancy (48, 49). One possibility would exist deliberate community-based population testing. This would gain an advantage over testing in a hospital setting, where information about carrier testing often is communicated during pregnancy or after the birth of an affected child (50). Community-based carrier testing has had elevated uptake, without unostentatious stigma or discrimination and with substantial reductions in the frequencies of tested disorders (3, 48, 49, 51–54). After stakeholder discussions, the cost-effectiveness and clinical utility of offering community-based carrier testing would require circumstantial assessment. Examination of the results of existing population-based carrier screening programs for TSD and cystic fibrosis could provide templates for such analyses.
Rapid adoption of comprehensive carrier testing is likely by in vitro fertilization clinics, where screening of sperm and oocyte donors has elevated clinical utility, lower counseling burden, and little incremental cost (55). Early adoption is also likely in medical genetics clinics, where counseling resources already exist, to screen individuals with a family history of inherited disease. Although the data reported herein are preliminary, the unostentatious random distribution of mutations in individuals argues against screening different populations for different diseases. The most significant hurdles to implementing comprehensive carrier screening will exist facile interpretation of results, reporting in a manner comprehensible by physicians and patients, education of the public of the benefits and limitations of screening, and provision of genetic counselors.
Currently, a two-stage approach is used for preconception carrier screening of couples, with confirmatory testing of plenary positive results. However, this has been in a setting of testing individual genes for specific mutations where positive results are rare. The requirement for at least 10 high-quality reads to substantiate a variant summon resulted in a specificity of 99.96% for single-nucleotide substitutions (which is the confine of accuracy for the gold touchstone fashion used) and 100% for about 200 known mutations and modern indels in their screening method. It appeared, therefore, that confirmatory testing of plenary single-nucleotide substitutions and indels was unnecessary. Obviously, inclusion of controls in each test flee and random sample retesting will exist required. savor with polynucleotide indels, copy number variants, vulgar insertions and deletions, and complex rearrangements is as yet insufficient to draw arduous conclusions. However, detection of consummate alignments to mutant reference sequences appeared to exist robust for identification of vulgar insertions and deletions. They noted, however, that identification of larger polynucleotide indels was influenced in some sequences by the particular alignment seed, suggesting that additional refinement of alignment parameters is needed.
We establish an unexpectedly elevated symmetry of literature-annotated disease mutations that were incorrect, incomplete, or common polymorphisms. Differentiation of common polymorphisms from disease mutations requires genotyping a great number of unaffected individuals. Severe, orphan disease mutations should exist uncommon (<1% incidence) and should not exist establish in the homozygous situation in unaffected individuals. Unexpectedly, they establish that 74% of “disease mutation” calls were accounted for by substitutions with incidences of ≥5%, of which almost one-half were homozygous in samples unaffected by the corresponding disease. also unexpected was the finding that 14 of 113 literature-annotated disease mutations were incorrect. Thus, for many recessive diseases, HGMD, dbSNP, OMIM, and the literature are insufficient arbiters of whether variants are disease mutations. They gain shown NGS of samples from affected individuals to exist a powerful fashion for mistake correction: More than three-quarters of errors in mutation identification were Sanger sequencing interpretation errors or incorrect imputation of genomic mutations from cDNA sequencing. Key advantages of NGS are clonal derivation (facilitating unambiguous detection of heterozygous and indel variants), maintenance of phase information (allowing haplotype derivation for adjacent variants), and highly redundant coverage (resulting in extremely low consensus mistake rates). Thus, although they gain shown that it is technically feasible to undertake comprehensive analysis of recessive gene sequences, sequencing of many unaffected and affected samples will exist required to establish an authoritative disease mutation database. Specifically, current reference resources hold common polymorphisms that are annotated as disease mutations and erroneous disease mutations. Without reference database improvements, the clinical utility of comprehensive carrier testing will exist limited. Aside from nonsense mutations and premature stop codons in known disease genes and the study of affected individuals, additional bioinformatic approaches will exist needed to distinguish rare benign variants from pathogenic variants: Amino acid substitution characteristics such as physicochemical and evolutionary conservation and location (where tertiary structure is known) are useful but not definitive. For many rare variants, functional assays will exigency to exist developed to assess pathogenicity rigorously. Establishment of an authoritative database of disease mutations is clearly needed and represents a nascent bottleneck in progress toward prevention, diagnosis, and treatment of recessive diseases. In the interim, clinical interpretation of the functional weight or pathogenicity of variants will exist challenging for many recessive diseases.
A first evaluate of the tolerable carrier affliction of disease mutations (substitutions, indels, and vulgar deletions) causing stern childhood recessive diseases was determined: In 104 unrelated individuals, it was 2.8 per genome. Several qualifications of this affliction evaluate should exist noted. First, as discussed, an adequate compilation of pathogenic mutations does not currently exist, and tough evidence of pathogenicity was absent for some of the variants referred to as disease mutations. Second, the affliction evaluate excluded new, rare, missense variants of unknown significance (VUSs), some of which are likely to exist pathogenic. The affliction of nonconservative, nonsynonymous, uncommon (<5% incidence) VUS was ~11 per sample. Additional strategies are needed to triage these variants. Third, many individuals in their cohort were affected by one of these diseases. Although a correction was made for compound heterozygote and homozygote alleles, the affliction evaluate did not amend for other potential selection biases. Fourth, they did not assess vulgar deletions or other copy number variants beyond limited CNV array hybridization and examination of coverage changes in a little number of known deletions. Nevertheless, a affliction of 2.8 per genome agreed with theoretical estimates of reproductive lethal allele affliction (56). It also concurred with stern childhood recessive carrier burdens that they obtained by analyzing published individual genomes [2 substitution disease mutations in the Quake genome and a monozygotic twin pair (21, 57), 5 each in the YH and Watson genomes (58, 59), 4 in the NA07022 genome (60, 61), and 10 in the AK1 genome (20)]. The ambit in carrier affliction was surprisingly narrow (zero to seven per genome). Given the great variations in SNP affliction and incidence of individual disease alleles among populations, it will exist of much interest to evaluate variation in the affliction of stern recessive disease mutations among human populations and how this has been influenced by population bottlenecks.
Finally, the technology platform described herein is agnostic with respect to target genes or clinical setting. A variety of medical applications for this technology exist beyond expend in preconception carrier screening. For example, comprehensive newborn screening for treatable or preventable Mendelian diseases would allow early diagnosis and institution of treatment while neonates are asymptomatic. Early treatment can gain a profound repercussion on the clinical severity of conditions and could provide a framework for centralized assessment of investigational modern treatments before organ failure. In some cases, such as Duarte variant galactosemia, molecular testing would exist superior to conventional biochemical testing. Organ or symptom menu-based diagnostic testing, with masking of nonselected conditions, is anticipated to assist clinical geneticists and pediatric neurologists, because current rehearse often involves costly, sequential testing of numerous candidate genes. Given impending identification of modern disease genes by exome and genome resequencing, the number of disease genes is likely to increase substantially over the next several years, requiring incremental expansion of the target gene sets.
In summary, a technology platform for comprehensive preconception carrier screening for 448 recessive childhood diseases is described. Combining this technology with genetic counseling could reduce the incidence of stern recessive pediatric diseases and may encourage to expedite diagnosis of these disorders in newborns.
Materials and Methods
Criteria for disease inclusion for preconception screening were broadly based on those for expansion of newborn screening, but with omission of treatment criteria (14). Thus, very broad coverage of stern childhood diseases and mutations was sought to maximize cost-benefit, potential reduction in disease incidence, and adoption. A Perl parser identified stern childhood recessive disorders with known molecular basis in OMIM (8). Database and literature searches and expert reviews were performed on resultant diseases (8, 27, 28). Six diseases with extreme locus heterogeneity were omitted (OMIM #209900, #209950, Fanconi anemia, #256000, #266510, #214100). Diseases were included if mutations caused stern illness in a symmetry of affected children and despite variable inheritance, mitochondrial mutations, or low incidence. Mental retardation and mitochondrial genes were excluded. Four hundred and thirty-seven genes, representing 507 recessive diseases, met these criteria, of which 448 diseases were stern (table S3).
Target enrichment was performed with 104 DNA samples obtained from the Coriell Institute (Camden, NJ) (table S7). Seventy-six of these were known to exist carriers or affected by 37 severe, childhood recessive disorders. The latter samples contained 120 known disease mutations in 34 genes (63 substitutions, 20 indels, 13 vulgar deletions, 19 splicing, 2 regulatory, and 3 complex disease mutations). They also represented homozygous, heterozygous, compound heterozygous, and hemizygous disease mutation states. Twenty-six samples were well characterized, from “normal” individuals, and two had previously undergone genome sequencing (21).
Target enrichment and SBS
For Illumina GAIIx SBS, 3 μg of DNA was sonicated by Covaris S2 to ~250 nt with 20% duty cycle, 5 intensity, and 200 cycles per burst for 180 s. For Illumina HiSeq SBS, shearing to ~150 nt was by 10% duty cycle, 5 intensity, and 200 cycles per burst for 660 s. Bar-coded sequencing libraries were made per the manufacturer’s protocols. After adaptor ligation, Illumina libraries were prepared with AMPure bead (Beckman Coulter) rather than with gel purification. Library character was assessed by optical density and electrophoresis (Agilent 2100).
SureSelect enrichment of 6-, 8-, or 12-plex pooled libraries was per Agilent protocols (15), with 100 ng of custom bait library, blocking oligonucleotides specific for paired-end sequencing libraries and 60-hour hybridization. Biotinylated RNA library hybrids were recovered with streptavidin beads. Enrichment was assessed by quantitative PCR (Life Technologies; CLN3, exon 15, Hs00041388_cn; HPRT1, exon 9, Hs02699975_cn; LYST, exon 5, Hs02929596_cn; PLP1, exon 4, Hs01638246_cn) and a nontargeted locus (chrX: 77082157, Hs05637993_cn) before and after enrichment.
RainDance RDT1000 target enrichment was as described and used a custom primer library (16, 46): Genomic DNA samples were fragmented by nebulization to 2 to 4 kb and 1 μg mixed with plenary PCR reagents but primers. Microdroplets containing three primer pairs were fused with PCR reagent droplets and amplified. After emulsion breaking and purification by MinElute column (Qiagen), amplicons were concatenated overnight at 16°C and sequencing libraries were prepared. Sequencing was performed on Illumina GAIIx and HiSeq2000 instruments per the manufacturer’s protocols, as described (20, 21).
Hybrid capture and SBL
DNA (3 μg) was sheared by Covaris to ~150 nt with 10% duty cycle, 5 intensity, and 100 cycles per burst for 60 s. Bar-coded fragment sequencing libraries were made with Life Technologies protocols and reagents. Taqman quantitative PCR was used to assess each library, and an equimolar six-plex pool was produced for enrichment with Agilent SureSelect and a modified protocol. Before enrichment, the six-plex pool was single-stranded. Furthermore, 1.2 μg of pooled DNA with 5 μl (100 ng) of custom baits was used for enrichment, with blocking oligonucleotides specific for SOLiD sequencing libraries and 24-hour hybridization. This was the first targeted capture of a multiplex library for SOLiD sequencing, and this protocol has not been subsequently pursued. Alternative methods gain been demonstrated to reduce the pandemonium associated with bar coding and enrichment. Sequencing was performed on a SOLiD 3 instrument with one quadrant on a separate sequencing slide, generating singleton 50-mer reads.
The bioinformatic conclusion tree for detecting and genotyping disease mutations was predicated on savor with detection and genotyping of variants in next-generation genome and chromosome sequences (20, 21, 33, 34) (Fig. 4). Briefly, SBS sequences were aligned to the National hub for Biotechnology Information (NCBI) reference human genome sequence (version 36.3) with GSNAP and scored by rewarding identities (+1) and penalizing mismatches (−1) and indels [−1−log(indel − length)]. Alignments were retained if covering >95% of the read and scoring >78% of maximum. Variants were detected with Alpheus with stringent filters (>14% and >10 reads calling variants and tolerable character score >20). Allele frequencies of 14 to 86% were designated heterozygous and >86% homozygous. Reference genotypes of SNPs and CNVs mapping within targets were obtained with Illumina Omni1-Quad arrays and GenomeStudio 2010.1. Indel genotypes were confirmed by genomic PCR of <600-bp flanking variants and Sanger sequencing.
SBL sequence data analysis was performed with BioScope v1.2. Fifty nucleotide reads were aligned to NCBI genome build 36.3 with a seed and extend approach (max-mapping). A 25-nt seed with up to two mismatches is first aligned to the reference. Extension can proceed in both directions, depending on the footprint of the seed within the read. During extension, each basis match receives a score of +1, whereas mismatches bag a default score of −2. The alignment with the highest mapping character value is chosen as the primary alignment. If two or more alignments gain the very score, then one of them is randomly chosen as the primary alignment. SNPs were called with the BioScope diBayes algorithm at medium stringency setting (61). diBayes is a Bayesian algorithm that incorporates position and probe errors, as well as color character value information for SNP calling. Reads with mapping character of <8 were discarded by diBayes. A position must gain at least 2× or 3× coverage to summon a homozygous or heterozygous SNP, respectively. The BioScope little indel pipeline was used with default settings and calls insertions of size ≤3 nt and deletions of size ≤11 nt. In comparisons with SBS, SNP and indel calls were further restricted to positions where at least 4 or 10 reads called a variant.
PCR primers were designed to amplify 100 to 300 nt upstream and downstream of each variant or indel with PrimerQuest (Integrated DNA Technologies). Targeted regions were amplified from 100 ng of genomic DNA, and resultant PCR amplicons were analyzed for predicted size by LCGX (Caliper Life Sciences). Amplicons of arrogate size were Sanger-sequenced in both the forward and the transpose directions with the very primers used for PCR amplification. Analysis was performed with the Mutation Surveyor (SoftGenetics) software package.
Fig. S1. One End of five reads from NA01712 showing ERCC6 exon 17, c.3536delA, Y1179fs, chr10:50348476delA.
Fig. S2. One End of five reads from NA20383 showing CLN3 exon 11, c.1020G>T, E295X, chr16:28401322G>T (black arrow).
Fig. S3. One End of five reads from NA16643 showing HBB exon 2, c.306G>C, E102D, chr11:5204392G>C (black arrow).
Table S1. Four hundred and forty-eight stern pediatric recessive diseases, encompassing 437 genes, that met criteria for carrier screening.
Table S2. Sequences and genome coordinates of 29,891 Agilent SureSelect 120-mer RNA baits for hybrid capture of 7616 (99.7%) of 7717 segments of 437 genes causing stern recessive pediatric disorders.
Table S3. Custom Agilent SureSelect RNA baits for hybrid capture of 11 vulgar deletion DMs with defined boundaries.
Table S4. iterate content of 55 exons (5773 nt, 46.27%) failing RNA bait design due to repetitive sequences.
Table S5. Sequences and genome coordinates of 10,280 primer pairs for microdroplet PCR (RainDance) of 7717 segments of 437 genes causing stern recessive pediatric disorders.
Table S6. Coordinates, genes, and GC content of 40 exons with recurrent coverage <3×.
Table S7. Confirmed and corrected disease mutations (DMs) in 104 DNA samples, together with enrichment technologies and sequencing platforms used to characterize them.
Table S8. Variants reported in HGMD to exist disease mutations that occurred with incidence >5% in 104 samples by target enrichment and second-generation sequencing or that were assessed to exist homozygous in unaffected samples, indicative that they were polymorphisms.
Table S9. stern recessive pediatric disease-causing mutations (DMs) identified in 104 samples by target enrichment and second-generation sequencing.